đź“Š Evidence-Based Reference
amecath and amecath uniqath soft short term dual hemodialysis catheterization kits
Ameco Medical Industries
Summary: The Amecath and Uniqath Soft Short Term Dual Hemodialysis Catheterization Kits are used for temporary vascular access in hemodialysis. Cleared by the FDA via the 510(k) pathway, these devices are supported by 10 studies, though none directly related to the device.
FDA Clearance Information
Pathway
510K
Number
K110793 ↗
Decision Date
December 16, 2011
Product Code
MPB
Device Class
Class 2
Evidence
0 studies
The Amecath and Uniqath catheters were cleared by the FDA through the 510(k) pathway on December 16, 2011. Manufactured by Ameco Medical Industries, these devices are classified as Class 2 under product code MPB.
What It Is
These catheters are designed for short-term hemodialysis access, providing a conduit for blood to be removed, filtered, and returned to the body. They are intended for use in patients requiring temporary dialysis access.
Clinical Applications
Commonly used in clinical settings where immediate hemodialysis access is needed, such as in acute kidney injury or when awaiting permanent access placement. They are typically used in hospital or dialysis center settings.
Evidence Summary
The literature includes 10 studies, none of which directly evaluate the Amecath or Uniqath catheters. The studies span various topics related to soft robotics and materials science, published between 2023 and 2024.
Reported Outcomes
Published studies report advancements in soft robotics and materials science, but none directly assess the clinical outcomes of the Amecath or Uniqath catheters. Therefore, specific efficacy findings for these devices are not available from the provided evidence.
Safety Profile
Reported complications include no direct safety data from the provided studies, as they do not focus on the Amecath or Uniqath catheters. Further research is needed to determine specific safety outcomes.
Evidence Limitations
The current evidence lacks direct studies on the Amecath and Uniqath catheters, highlighting a gap in clinical research. Future studies should focus on device-specific outcomes and safety to provide comprehensive data.
Frequently Asked Questions
What are the clinical indications for Amecath and Uniqath catheters?
These catheters are indicated for short-term hemodialysis access in patients requiring temporary vascular access.
What outcomes have been reported in clinical studies?
No specific outcomes for these catheters are reported in the provided studies.
What complications have been reported?
No specific complications for these catheters are reported in the provided studies.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.